Brokerages Anticipate Kitov Pharmaceuticals Holdings Ltd (KTOV) Will Announce Earnings of -$0.01 Per Share

Equities analysts expect Kitov Pharmaceuticals Holdings Ltd (NASDAQ:KTOV) to report ($0.01) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Kitov Pharmaceuticals’ earnings. The business is expected to issue its next earnings report on Monday, May 7th.

On average, analysts expect that Kitov Pharmaceuticals will report full year earnings of ($0.01) per share for the current fiscal year. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Kitov Pharmaceuticals.

Separately, HC Wainwright raised shares of Kitov Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $10.00 price target on the stock in a report on Tuesday, November 21st.

Shares of Kitov Pharmaceuticals (NASDAQ:KTOV) opened at $2.49 on Thursday. Kitov Pharmaceuticals has a fifty-two week low of $1.27 and a fifty-two week high of $3.44.

WARNING: “Brokerages Anticipate Kitov Pharmaceuticals Holdings Ltd (KTOV) Will Announce Earnings of -$0.01 Per Share” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at

About Kitov Pharmaceuticals

Kitov Pharma Ltd, formerly Kitov Pharmaceuticals Holdings Ltd, is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.

Get a free copy of the Zacks research report on Kitov Pharmaceuticals (KTOV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Kitov Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kitov Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply